Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 177Lung Neoplasms 59Neoplasms 24Neoplasm Metastasis 17Parkinson Disease 4, Autosomal Dominant Lewy Body 13Mesothelioma, Malignant 12Carcinoma 11Colorectal Neoplasms 10Mesothelioma 9Meningeal Carcinomatosis 8Melanoma 7Brain Neoplasms 7Pancreatic Neoplasms 6Adenocarcinoma of Lung 6Advanced Solid Tumors 5Uterine Cervical Neoplasms 4Ovarian Neoplasms 4Neoplasms by Site 4Colonic Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Non-squamous Non-small Cell Lung Cancer 3Neoplasms by Histologic Type 3NSCLC 3Lung Diseases 3Head and Neck Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma, Bronchogenic 3Adenocarcinoma 3Thoracic Neoplasms 2

Interventions

ruxolitinib 23Cyclophosphamide 13Whole-Body Irradiation 10Tacrolimus 9Mycophenolic Acid 9fludarabine phosphate 8fludarabine 8Stem Cell Transplantation 8Specimen Handling 7Peripheral Blood Stem Cell Transplantation 7Busulfan 5Azacitidine 5navitoclax 4Sirolimus 4Melphalan 4Biopsy 4luspatercept 3fedratinib 3Methotrexate 3Cyclosporine 3venetoclax 2selinexor 2parsaclisib 2letermovir 2itacitinib 2bomedemstat 2Injections 2INCB057643 2INCB039110 2Hematopoietic Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Primary Myelofibrosis × Pemetrexed × 1 year × Clear all
NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

iOnctura

Phase 1 Active not recruiting
210 enrolled
DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡